BACKGROUND: Prostate cancer survivors commonly experience late-onset lower urinary tract symptoms following radiotherapy. We aimed to compare lower urinary tract symptoms in patients treated with stereotactic body radiotherapy (SBRT) to those treated with a combination of lower dose SBRT and supplemental intensity-modulated radiotherapy (SBRT + IMRT). METHODS: Subjects with localized prostate carcinoma scheduled to receive SBRT or a combination of SBRT and IMRT were enrolled and followed for up to 2 years after treatment completion. Participants treated with SBRT received 35-36.25 Gy in 5 fractions, while those treated with SBRT + IMRT received 19.5 Gy of SBRT in 3 fractions followed by 45-50.4 Gy of IMRT in 25-28 fractions. Urinary symptoms were measured using the American Urological Association (AUA) Symptom Score. RESULTS: Two hundred patients received SBRT (52% intermediate risk, 37.5% low risk according to D'Amico classification) and 145 patients received SBRT + IMRT (61.4% high risk, 35.2% intermediate risk). Both groups experienced a transient spike in urinary symptoms 1 month after treatment. More severe late urinary flare (increase in AUA scores ≥ 5 points from baseline to 1 year after treatment completion and an AUA score ≥ 15 at 1 year after treatment) was experienced by patients who received SBRT compared to those treated with SBRT + IMRT. CONCLUSION: Participants who received SBRT and supplemental IMRT experienced less severe late urinary flare 1 year after treatment compared to those who received higher dose SBRT alone. This information can be used by clinicians to provide patients with anticipatory counseling to mitigate any psychological burden that comes with unanticipated late urinary toxicities.
BACKGROUND: Prostate cancer survivors commonly experience late-onset lower urinary tract symptoms following radiotherapy. We aimed to compare lower urinary tract symptoms in patients treated with stereotactic body radiotherapy (SBRT) to those treated with a combination of lower dose SBRT and supplemental intensity-modulated radiotherapy (SBRT + IMRT). METHODS: Subjects with localized prostate carcinoma scheduled to receive SBRT or a combination of SBRT and IMRT were enrolled and followed for up to 2 years after treatment completion. Participants treated with SBRT received 35-36.25 Gy in 5 fractions, while those treated with SBRT + IMRT received 19.5 Gy of SBRT in 3 fractions followed by 45-50.4 Gy of IMRT in 25-28 fractions. Urinary symptoms were measured using the American Urological Association (AUA) Symptom Score. RESULTS: Two hundred patients received SBRT (52% intermediate risk, 37.5% low risk according to D'Amico classification) and 145 patients received SBRT + IMRT (61.4% high risk, 35.2% intermediate risk). Both groups experienced a transient spike in urinary symptoms 1 month after treatment. More severe late urinary flare (increase in AUA scores ≥ 5 points from baseline to 1 year after treatment completion and an AUA score ≥ 15 at 1 year after treatment) was experienced by patients who received SBRT compared to those treated with SBRT + IMRT. CONCLUSION: Participants who received SBRT and supplemental IMRT experienced less severe late urinary flare 1 year after treatment compared to those who received higher dose SBRT alone. This information can be used by clinicians to provide patients with anticipatory counseling to mitigate any psychological burden that comes with unanticipated late urinary toxicities.
Authors: Sean P Collins; Simeng Suy; Leonard N Chen; Brian T Collins; John Lynch; Anatoly Dritschilo Journal: J Clin Oncol Date: 2014-09-02 Impact factor: 44.544
Authors: Eric K Oermann; Rebecca S Slack; Heather N Hanscom; Sue Lei; Simeng Suy; Hyeon U Park; Joy S Kim; Benjamin A Sherer; Brian T Collins; Andrew N Satinsky; K William Harter; Gerald P Batipps; Nicholas L Constantinople; Stephen W Dejter; William C Maxted; James B Regan; John J Pahira; Kevin G McGeagh; Reena C Jha; Nancy A Dawson; Anatoly Dritschilo; John H Lynch; Sean P Collins Journal: Technol Cancer Res Treat Date: 2010-10
Authors: Aaron W Pederson; Janine Fricano; David Correa; Charles A Pelizzari; Stanley L Liauw Journal: Int J Radiat Oncol Biol Phys Date: 2010-12-14 Impact factor: 7.038
Authors: George Rodrigues; Padraig Warde; Tom Pickles; Juanita Crook; Michael Brundage; Luis Souhami; Himu Lukka Journal: Can Urol Assoc J Date: 2012-04 Impact factor: 1.862
Authors: Carol E DeSantis; Chun Chieh Lin; Angela B Mariotto; Rebecca L Siegel; Kevin D Stein; Joan L Kramer; Rick Alteri; Anthony S Robbins; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2014-06-01 Impact factor: 508.702
Authors: Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson Journal: N Engl J Med Date: 2013-01-31 Impact factor: 91.245
Authors: Jennifer A Woo; Leonard N Chen; Aditi Bhagat; Eric K Oermann; Joy S Kim; Rudy Moures; Thomas Yung; Siyuan Lei; Brian T Collins; Deepak Kumar; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins Journal: Front Oncol Date: 2014-05-26 Impact factor: 6.244
Authors: Daniel Y Joh; Leonard N Chen; Gerald Porter; Aditi Bhagat; Sumit Sood; Joy S Kim; Rudy Moures; Thomas Yung; Siyuan Lei; Brian T Collins; Andrew W Ju; Simeng Suy; John Carroll; John H Lynch; Anatoly Dritschilo; Sean P Collins Journal: Radiat Oncol Date: 2014-12-12 Impact factor: 3.481